{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:32:24Z","timestamp":1786735944589,"version":"build-2736575974"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/1673-5374.237108","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T10:16:10Z","timestamp":1534500970000},"page":"1493","source":"Crossref","is-referenced-by-count":45,"title":["Neuroprotection by immunomodulatory agents in animal models of Parkinson\u2019s disease"],"prefix":"10.4103","volume":"13","author":[{"given":"PhilipV","family":"Peplow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.237108-1","doi-asserted-by":"crossref","unstructured":"Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, Kovacs Z, Lewerenz J, Lisak D, Maher P, Mausberg AK, Quasthoff K, Zimmermann C, Hartung HP, Methner A (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9:163.","DOI":"10.1186\/1742-2094-9-163"},{"key":"key-10.4103\/1673-5374.237108-2","doi-asserted-by":"crossref","unstructured":"Athauda D, Foltynie T (2015) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 11:25-40.","DOI":"10.1038\/nrneurol.2014.226"},{"key":"key-10.4103\/1673-5374.237108-3","doi-asserted-by":"crossref","unstructured":"Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2008) Diabetes in patients with idiopathic Parkinson\u2019s disease. Diabetes Care 31:1808-1812.","DOI":"10.2337\/dc08-0479"},{"key":"key-10.4103\/1673-5374.237108-4","unstructured":"Bik W, Skwarlo-Sonta K, Szelagiewicz J, Wolinska-Witort E, Chmielowska M, Martynska L, Baranowska-Bik A, Baranowska B (2008) Involvement of the cocaine-amphetamine regulated transcript peptide (CART 55-102) in the modulation of rat immune cell activity. Neuro Endocrinol Lett 29:359-365."},{"key":"key-10.4103\/1673-5374.237108-5","doi-asserted-by":"crossref","unstructured":"Bodera P, Stankiewicz W (2011) Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. Recent Pat Endocr Metab Immune Drug Discov 5:192-196.","DOI":"10.2174\/187221411797265890"},{"key":"key-10.4103\/1673-5374.237108-6","doi-asserted-by":"crossref","unstructured":"Braak H, Sastre M, Del Tredici K (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebtain parallels stages of intraneuronal pathology in sporadic Parkinson\u2019s disease. Acta Neuropathol 114:231-241.","DOI":"10.1007\/s00401-007-0244-3"},{"key":"key-10.4103\/1673-5374.237108-7","doi-asserted-by":"crossref","unstructured":"Cheshier JE, Ardestani-Kaboudanian S, Liang B, Araghiniknam M, Chung S, Lane L, Castro A, Watson RR (1995) Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Life Sci 58:PL87-96.","DOI":"10.1016\/0024-3205(95)02303-8"},{"key":"key-10.4103\/1673-5374.237108-8","doi-asserted-by":"crossref","unstructured":"Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, Przedborski S (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson\u2019s disease in mice. J Neurosci 25:6594-6600.","DOI":"10.1523\/JNEUROSCI.0970-05.2005"},{"key":"key-10.4103\/1673-5374.237108-9","doi-asserted-by":"crossref","unstructured":"Clarke LE, Liddelow SA, Chakraborty C, M\u00fcnch AE, Heiman M, Barres BA (2018) Normal aging induces A1-like astrocyte reactivity. Proc Nat Acad Sci U S A 115:E1896-1905.","DOI":"10.1073\/pnas.1800165115"},{"key":"key-10.4103\/1673-5374.237108-10","doi-asserted-by":"crossref","unstructured":"Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I (1970) Similarities between neurological effects of L-dopa and of apomorphine. N Eng J Med 282:31-33.","DOI":"10.1056\/NEJM197001012820107"},{"key":"key-10.4103\/1673-5374.237108-11","unstructured":"Cz\u0142onkowska A, Kurkowska-Jastrz\u0119bska I, Cz\u0142onkowski A, Peter D, Stefano GB (2002) Immune processes in the pathogenesis of Parkinson\u2019s disease \u2013 a potential role for microglia and nitric oxide. Med Sci Monit 8:RA165-177."},{"key":"key-10.4103\/1673-5374.237108-12","doi-asserted-by":"crossref","unstructured":"Daneshzand M, Faezlpour M, Barkana BD (2017a) Hyperbolic modeling of subthalamic nucleus cells to investigate the effect of dopamine depletion. Comput Intell Neurosci 2017:5472752.","DOI":"10.1155\/2017\/5472752"},{"key":"key-10.4103\/1673-5374.237108-13","doi-asserted-by":"crossref","unstructured":"Daneshzand M, Faezlpour M, Barkana BD (2017b) Computational stimulation of the basal ganglia neurons with cost effective delayed Gaussian waveforms. Front Comput Neurosci 11:73.","DOI":"10.3389\/fncom.2017.00073"},{"key":"key-10.4103\/1673-5374.237108-14","doi-asserted-by":"crossref","unstructured":"DeMattei M, Levi AC, Fariello RG (1986) Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci Lett 72:37-42.","DOI":"10.1016\/0304-3940(86)90614-2"},{"key":"key-10.4103\/1673-5374.237108-15","doi-asserted-by":"crossref","unstructured":"deSouza RM, Schapira AH (2017) Etiology and pathogenesis of Parkinson disease. In: Neurodegeneration, First Edition. (Schapira A, Wszolek Z, Dawson TM, Wood N, eds), pp 46-52. John Wiley & Sons Ltd.","DOI":"10.1002\/9781118661895.ch5"},{"key":"key-10.4103\/1673-5374.237108-16","doi-asserted-by":"crossref","unstructured":"Dickson DW (2001) Alpha synuclein and the Lewy body disorders. Curr Opin Neurol 14:423-432.","DOI":"10.1097\/00019052-200108000-00001"},{"key":"key-10.4103\/1673-5374.237108-17","doi-asserted-by":"crossref","unstructured":"Ejerskov P, Hultberg JG, Wang J, Carlsson R, Ambj\u00f8rn M, Kuss M, Liu Y, Porcu G, Kolkova K, Friis Rundsten C, Ruscher K, Pakkenberg B, Goldmann T, Loreth D, Prinz M, Rubinsztein DC, Issazadeh-Navikas S (2015) Lack of neuronal IFN-\u03b2-IFNAR causes Lewy body- and Parkinson\u2019s disease-like dementia. Cell 163:324-339.","DOI":"10.1016\/j.cell.2015.08.069"},{"key":"key-10.4103\/1673-5374.237108-18","doi-asserted-by":"crossref","unstructured":"Francardo V, Schmitz Y, Sulzer D, Cenci MA (2017) Neuroprotection and neurorestoration as experimental therapeutics for Parkinson\u2019s disease. Exp Neurol 298:137-147.","DOI":"10.1016\/j.expneurol.2017.10.001"},{"key":"key-10.4103\/1673-5374.237108-19","doi-asserted-by":"crossref","unstructured":"He J, Hu XP, Zeng Y, Li Y, Wu HQ, Qiu RZ, Ma WJ, Li T, Li CY, He ZD (2011) Advanced research on acetoside for chemistry and bioactivities. J Asian Nat Prod Res 13:449-464.","DOI":"10.1080\/10286020.2011.568940"},{"key":"key-10.4103\/1673-5374.237108-20","doi-asserted-by":"crossref","unstructured":"Jin F, Wu Q, Lu YF, Gong QH, Shi JS (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson\u2019s disease in rats. Eur J Pharmacol 600:78-82.","DOI":"10.1016\/j.ejphar.2008.10.005"},{"key":"key-10.4103\/1673-5374.237108-21","doi-asserted-by":"crossref","unstructured":"Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, Zhang X, Lou H (2015) Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson\u2019s disease by enhancing Nrf2 activity. Neuroscience 286:131-140.","DOI":"10.1016\/j.neuroscience.2014.11.047"},{"key":"key-10.4103\/1673-5374.237108-22","doi-asserted-by":"crossref","unstructured":"Jing X, Wei X, Ren M, Wang L, Zhang X, Lou H (2016) Neuroprotective effects of tanshinone I against 6-OHDA-induced oxidative stress in cellular and mouse model of Parkinson\u2019s disease through upregulating Nrf2. Neurochem Res 41:779-786.","DOI":"10.1007\/s11064-015-1751-6"},{"key":"key-10.4103\/1673-5374.237108-23","doi-asserted-by":"crossref","unstructured":"Kaminska B, Gaweda-Walerych K, Zawadzka M (2004) Molecular mechanisms of neuroprotective action of immnosuppressants - facts and hypotheses. J Cell Mol Med 8:45-58.","DOI":"10.1111\/j.1582-4934.2004.tb00259.x"},{"key":"key-10.4103\/1673-5374.237108-24","doi-asserted-by":"crossref","unstructured":"Kasper LH, Reder AT (2014) Immunomodulatory activity of interferon-beta. Ann Clin Trans Neurol 1:622-631.","DOI":"10.1002\/acn3.84"},{"key":"key-10.4103\/1673-5374.237108-25","doi-asserted-by":"crossref","unstructured":"Kenarova B, Neychev H, Hadjiivanova C, Petkov VD (1990) Immunomodulating activity of ginsenoside Rg1 from Panax ginseng. Jpn J Pharmacol 54:447-454.","DOI":"10.1254\/jjp.54.447"},{"key":"key-10.4103\/1673-5374.237108-26","doi-asserted-by":"crossref","unstructured":"Khan MM, Kempuraj D, Thangavel R, Zaheer A (2013) Protection of MPTP-induced neuroinflammation and neurodegeneration by pycnogenol. Neurochem Int 62:379-388.","DOI":"10.1016\/j.neuint.2013.01.029"},{"key":"key-10.4103\/1673-5374.237108-27","doi-asserted-by":"crossref","unstructured":"Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36.","DOI":"10.1186\/1756-8722-2-36"},{"key":"key-10.4103\/1673-5374.237108-28","doi-asserted-by":"crossref","unstructured":"Kovarik JM, Schmouder RL, Slade AJ (2004) Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 26:585-587.","DOI":"10.1097\/00007691-200412000-00001"},{"key":"key-10.4103\/1673-5374.237108-29","doi-asserted-by":"crossref","unstructured":"Lakshmikanth T, Heuts F, Muvva SS, Wallin RP, Persson AK, Fauriat C, Applequist SE, Ljunggren HG, H\u00f6glund P, K\u00e4rre K, Svensson M, Juarez JG (2016) In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation. Eur J Immunol 46:1758-1769.","DOI":"10.1002\/eji.201545991"},{"key":"key-10.4103\/1673-5374.237108-30","doi-asserted-by":"crossref","unstructured":"Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46:598-605.","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F"},{"key":"key-10.4103\/1673-5374.237108-31","doi-asserted-by":"crossref","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38-48.","DOI":"10.1038\/nrn3406"},{"key":"key-10.4103\/1673-5374.237108-32","doi-asserted-by":"crossref","unstructured":"Lee JC, Park JH, Park OK, Kim IH, Yan BC, Ahn JH, Kwon SH, Choi JH, Kim JD, Won MH (2013) Neuroprotective effects of tanshinone I from Danshen extract in a mouse model of hypoxia-ischemia. Anat Cell Biol 46:183-190.","DOI":"10.5115\/acb.2013.46.3.183"},{"key":"key-10.4103\/1673-5374.237108-33","doi-asserted-by":"crossref","unstructured":"Lestes-Becker I, Garc\u00eda-Yag\u00fce AJ, Scannevin RH, Casarejos MJ, K\u00fcgler S, R\u00e1bano A, Cuadrado A (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinpathy in Parkinson\u2019s disease. Antioxid Redox Signal 25:61-77.","DOI":"10.1089\/ars.2015.6549"},{"key":"key-10.4103\/1673-5374.237108-34","doi-asserted-by":"crossref","unstructured":"Liddelow SA, Barres BA (2017) Reactive astrocytes: production, function, and therapeutic potential. Immunity 46:957-967.","DOI":"10.1016\/j.immuni.2017.06.006"},{"key":"key-10.4103\/1673-5374.237108-35","doi-asserted-by":"crossref","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M\u00fcnch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, et al. (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 54:481-487.","DOI":"10.1038\/nature21029"},{"key":"key-10.4103\/1673-5374.237108-36","doi-asserted-by":"crossref","unstructured":"Liu B, Gao HM, Hong JS (2003) Parkinson\u2019s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065-1073.","DOI":"10.1289\/ehp.6361"},{"key":"key-10.4103\/1673-5374.237108-37","doi-asserted-by":"crossref","unstructured":"Liu B, Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1-7.","DOI":"10.1124\/jpet.102.035048"},{"key":"key-10.4103\/1673-5374.237108-38","doi-asserted-by":"crossref","unstructured":"Maijenburg M, Gilissen C, Veltman J, Kleijer M, Mudde-Jadra C, Weijer K, ten Brinke A, van Tiel C, de Vries C, van der Schoot E, Voermans C (2010) Nur77 and Nurr 1, two novel players in MSC migration and immune function. Blood 116:3854.","DOI":"10.1182\/blood.V116.21.3854.3854"},{"key":"key-10.4103\/1673-5374.237108-39","unstructured":"Marsden CD (1983) Neuromelanin and Parkinson\u2019s disease. J Neural Transm Suppl 19:121-141."},{"key":"key-10.4103\/1673-5374.237108-40","doi-asserted-by":"crossref","unstructured":"Martiney JA, Rajan AJ, Charles PC, Cerami A, Ulrich PC, Macphail S, Tracey KJ, Brosnan CF (1998) Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. J Immunol 160:5588-5595.","DOI":"10.4049\/jimmunol.160.11.5588"},{"key":"key-10.4103\/1673-5374.237108-41","doi-asserted-by":"crossref","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38:1285-1291.","DOI":"10.1212\/WNL.38.8.1285"},{"key":"key-10.4103\/1673-5374.237108-42","doi-asserted-by":"crossref","unstructured":"Noelker C, Stuckenholz V, Reese JP, Alvarez-Fischer D, Sankowski R, Rausch T, Oertel WH, Hartmann A, van Patten S, Al-Abed Y, Bacher M (2013) CNI-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the acute MPTP mouse model of Parkinson\u2019s disease. Neurodegener Dis 12:103-110.","DOI":"10.1159\/000342714"},{"key":"key-10.4103\/1673-5374.237108-43","doi-asserted-by":"crossref","unstructured":"Oh SH, Lee SC, Kim DY, Kim HN, Shin JY, Ye BS, Lee PH (2017) Mesenchymal stem cells stabilize axonal transports for autophagic clearance of \u03b1-synuclein in Parkinsonian models. Stem Cells 35:1934-1947.","DOI":"10.1002\/stem.2650"},{"key":"key-10.4103\/1673-5374.237108-44","doi-asserted-by":"crossref","unstructured":"Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72:S1-136.","DOI":"10.1212\/WNL.0b013e3181a1d44c"},{"key":"key-10.4103\/1673-5374.237108-45","doi-asserted-by":"crossref","unstructured":"Palencia G, Garcia E, Osorio-Rico L, Trejo-Sol\u00eds C, Escamilla-Ram\u00edrez A, Sotelo J (2015) Neuroprotective effect of thalidomide on MPTP-induced toxicity. Neurotoxicology 47:82-87.","DOI":"10.1016\/j.neuro.2015.02.004"},{"key":"key-10.4103\/1673-5374.237108-46","doi-asserted-by":"crossref","unstructured":"Qin XY, Li T, Yan L, Liu QS, Tian Y (2010) Tanshinone IIA protects against immune-mediated liver injury through activation of T-cell subsets and regulation of cytokines. Immunopharmacol Immunotoxicol 32:51-55.","DOI":"10.3109\/08923970903120997"},{"key":"key-10.4103\/1673-5374.237108-47","doi-asserted-by":"crossref","unstructured":"Rai SN, Birla H, Zahra W, Singh SS, Singh SP (2017) Immunomodulation of Parkinson\u2019s disease using Mucuna pruriens (Mp). J Chem Neuroanat 85:27-35","DOI":"10.1016\/j.jchemneu.2017.06.005"},{"key":"key-10.4103\/1673-5374.237108-48","doi-asserted-by":"crossref","unstructured":"Ren B, Zhang YX, Zhou HX, Sun FW, Zhang ZF, Wei Z, Zhang CY, Si DW (2015) Tanshinione IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson\u2019s disease. J Neurol Sci 348:142-152.","DOI":"10.1016\/j.jns.2014.11.026"},{"key":"key-10.4103\/1673-5374.237108-49","doi-asserted-by":"crossref","unstructured":"Ren M, Han M, Wei X, Guo Y, Shi H, Zhang X, Perez RG, Lou H (2017) FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models. Neurochem Res 42:686-696.","DOI":"10.1007\/s11064-016-2125-4"},{"key":"key-10.4103\/1673-5374.237108-50","doi-asserted-by":"crossref","unstructured":"Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA (2009) Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 73:1752-1758.","DOI":"10.1212\/WNL.0b013e3181c34af5"},{"key":"key-10.4103\/1673-5374.237108-51","doi-asserted-by":"crossref","unstructured":"Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744-1754.","DOI":"10.1172\/JCI29178"},{"key":"key-10.4103\/1673-5374.237108-52","doi-asserted-by":"crossref","unstructured":"Segura-Aguilar J, Paris I, Mu\u00f1oz P, Ferrari E, Zecca L, Zucca F (2014) Protective and toxic roles of dopamine in Parkinson\u2019s disease. J Neurochem 129:898-915.","DOI":"10.1111\/jnc.12686"},{"key":"key-10.4103\/1673-5374.237108-53","doi-asserted-by":"crossref","unstructured":"Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O (2015) A Nurr1 agonist causes neuroprotection in a Parkinson\u2019s disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One 10:e0121072.","DOI":"10.1371\/journal.pone.0121072"},{"key":"key-10.4103\/1673-5374.237108-54","doi-asserted-by":"crossref","unstructured":"Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, Kim AS, Johnson JN, Bates D, King B, Case C, McGrogan M, Yankee EW, Schwartz NE (2016) Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke. A phase 1\/2a study. Stroke 47:1817-1824.","DOI":"10.1161\/STROKEAHA.116.012995"},{"key":"key-10.4103\/1673-5374.237108-55","doi-asserted-by":"crossref","unstructured":"Strassburger-Krogias K, Ellrichmann G, Krogias C, Altmeyer P, Chan A, Gold R (2014) Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord 7:232-238.","DOI":"10.1177\/1756285614544466"},{"key":"key-10.4103\/1673-5374.237108-56","doi-asserted-by":"crossref","unstructured":"Tajima K, Amakawa R, Ito T, Miyaji M, Takebayashi M, Fukuhara S (2003) Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 108: 321-328.","DOI":"10.1046\/j.1365-2567.2003.01585.x"},{"key":"key-10.4103\/1673-5374.237108-57","doi-asserted-by":"crossref","unstructured":"Tamburino A, Churchill MJ, Wan OW, Colino-Sanguino Y, Ippolito R, Bergstrand S, Wolf DA, Herz NJ, Sconce MD, Bj\u00f6rklund A, Meshul CK, Decressac M (2015) Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson\u2019s disease. Acta Neuropathol Commun 3:84.","DOI":"10.1186\/s40478-015-0263-6"},{"key":"key-10.4103\/1673-5374.237108-58","unstructured":"Tarsy D, 2017 https:\/\/www.uptodate.com\/contents\/potential-disease-modifying-therapies-for-parkinson-disease; accessed 21 March 2018."},{"key":"key-10.4103\/1673-5374.237108-59","doi-asserted-by":"crossref","unstructured":"Theodore S, Maragos W (2015) 6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson\u2019s disease. Immunopharmacol Immunotoxicol 37:393-399.","DOI":"10.3109\/08923973.2015.1070172"},{"key":"key-10.4103\/1673-5374.237108-60","doi-asserted-by":"crossref","unstructured":"Upadhya MA, Shelkar GP, Subhedar NK, Kokare DM (2016) CART modulates the effects of levodopa in rat model of Parkinson\u2019s disease. Behav Brain Res 301:262-272.","DOI":"10.1016\/j.bbr.2015.12.031"},{"key":"key-10.4103\/1673-5374.237108-61","doi-asserted-by":"crossref","unstructured":"Valera E, Mante M, Anderson S, Rockenstein E, Masliah E (2015) Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson\u2019s disease. J Neuroinflammation 12:93.","DOI":"10.1186\/s12974-015-0320-x"},{"key":"key-10.4103\/1673-5374.237108-62","doi-asserted-by":"crossref","unstructured":"Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, Kuypers DR, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt (2015) FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an \u03b1-synuclein-based rat model for Parkinson\u2019s disease. Neurobiol Aging 36:1559-1568.","DOI":"10.1016\/j.neurobiolaging.2015.01.014"},{"key":"key-10.4103\/1673-5374.237108-63","doi-asserted-by":"crossref","unstructured":"Vidal-Martinez G, Vargas-Medrano J, Gil-Tommee C, Medina D, Garza NT, Yang B, Segura-Ulate I, Dominguez SJ, Perez RG (2016) FTY720\/fingolimod reduces synucleinpathy and improves gut motility in A53T mice: Contributions of pro-brain-derived neurotrophic factor (pro-BDNF) and mature BDNF. J Biol Chem 291:20811-20821.","DOI":"10.1074\/jbc.M116.744029"},{"key":"key-10.4103\/1673-5374.237108-64","doi-asserted-by":"crossref","unstructured":"von Euler Chelpin M, Vorup-Jensen T (2017) Targets and mechanisms in prevention of Parkinson\u2019s disease through immunomodulatory treatments. Scand J Immunol 85:321-330.","DOI":"10.1111\/sji.12542"},{"key":"key-10.4103\/1673-5374.237108-65","doi-asserted-by":"crossref","unstructured":"Wang S, Jing H, Yang H, Liu Z, Guo H, Chai L, Hu L (2015) Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson\u2019s disease. J Ethnopharmacol 164:247-255.","DOI":"10.1016\/j.jep.2015.01.042"},{"key":"key-10.4103\/1673-5374.237108-66","doi-asserted-by":"crossref","unstructured":"Winklhofer KF, Haass C (2010) Mitochondrial dysfunction in Parkinson\u2019s disease. Biochim Biophys Acta 1802:29-44.","DOI":"10.1016\/j.bbadis.2009.08.013"},{"key":"key-10.4103\/1673-5374.237108-67","doi-asserted-by":"crossref","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Nat Acad Sci U S A 108:4194-4199.","DOI":"10.1073\/pnas.1100976108"},{"key":"key-10.4103\/1673-5374.237108-68","doi-asserted-by":"crossref","unstructured":"Yuan J, Ren J, Wang Y, He X, Zhao Y (2016) Acetoside binds to caspase-3 and exerts neuroprotection in the rotenone rat model of Parkinson\u2019s disease. PLoS One 11:e0162696.","DOI":"10.1371\/journal.pone.0162696"},{"key":"key-10.4103\/1673-5374.237108-69","unstructured":"Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D (2001) Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Path 54:414-418."},{"key":"key-10.4103\/1673-5374.237108-70","doi-asserted-by":"crossref","unstructured":"Zhang XS, Ha S, Wang XL, Shi YL, Duan SS, Li ZA (2015) Tanshinone IIA protects dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity through miR-153\/NF-E2-related factor 2\/antioxidant response element signaling pathway. Neuroscience 303:489-502.","DOI":"10.1016\/j.neuroscience.2015.06.030"},{"key":"key-10.4103\/1673-5374.237108-71","doi-asserted-by":"crossref","unstructured":"Zhao P, Yang X, Yang L, Li M, Wood K, Liu Q, Zhu X (2017) Neuroprotective effects of fingolimod in mouse models of Parkinson\u2019s disease. FASEB J 31:172-179.","DOI":"10.1096\/fj.201600751R"},{"key":"key-10.4103\/1673-5374.237108-72","doi-asserted-by":"crossref","unstructured":"Zhou TT, Zu G, Wang X, Zhang XG, Li S, Liang ZH, Zhao J (2015) Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson\u2019s disease. Int Immunopharmacol 29:334-343.","DOI":"10.1016\/j.intimp.2015.10.032"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:35:20Z","timestamp":1786732520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.237108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"alternative-id":["237108"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.237108","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}